Abstract:AIM: To evaluate the efficacy, safety and predictability of laser-assisted sub-epithelial keratectomy(LASEK)for the correction of hyperopia using the SCHWIND AMARIS platform.
METHODS: This retrospective single-surgeon study includes 66 eyes of 33 patients with hyperopia who underwent LASEK with mitomycin C(MMC). The median age of patients was 35.42±1.12y(ranging 18 to 56y). In each patient LASEK was performed using SCHWIND AMARIS excimer laser. Postoperatively clinical outcomes were evaluated in terms of predictability, safety, efficacy, subjective and objective refractions, uncorrected visual acuity(UCVA), best spectacle-corrected visual acuity(BSCVA)and adverse events.
RESULTS: The mean baseline refraction was 3.2±1.6 diopters(D)(ranging 0 to 7 D). The mean pre-operative and postoperative spherical equivalent(SE)were 2.34±1.76(ranging -1.25 to 7 D)and 0.30±0.84(ranging -0.2 to 0.8 D)respectively(P=0.001). The mean hyperopia was 0.63±0.84 D(ranging -1.75 to 2.76 D)6 to 12mo postoperatively. Likewise, the mean astigmatism was 0.68±0.43 D(range 0 to 2 D)with 51(77.3%)and 15(22.7%)eyes within ±1 and ±0.50 D respectively. The safety index and efficacy index were 1.08 and 1.6 respectively.
CONCLUSION:LASEK using SCHWIND AMARIS with MMC yields good visual and refractive results for hyperopia. Moreover, there were no serious complications.
